The field of RNA therapeutics has expanded incredibly in the past 30 years, and mRNA-based COVID-19 vaccines were just the start.
Clinical trials of an mRNA vaccine have begun, and researchers expect broadly positive outcomes in the fight against the widespread illness.
German doctors have reported success in treating patients with severe lupus, using cell treatments like those used for some forms of blood cancer.
Unequal access to the COVID-19 vaccine fuelled calls for a patent waiver, but any major change needs to ensure a better outcome for developing economies.
The case is growing stronger for COVID-19 vaccine mixing-and-matching, with recent data showing high efficacy and protection against SARS-CoV-2 virus strains.
Community pharmacies and pharmacists are important resources in Australia’s vaccine rollout, and right now they’re being under-utilised.
The rare blood-clotting issues associated with the Astra-Zeneca vaccine have recently made headlines, but it's too early to say whether it will increase overall vaccine hesitancy.
Dr Harry Al-Wassiti, Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS), answers the questions about the jab that's on everyone's mind.
We'll struggle to find a vaccine that works perfectly for people who need it most, despite what the headlines say is coming in 2021.
Early analysis suggests Pfizer's COVID-19 vaccine has an efficacy of more than 90%, but more data is still needed.
A behind-the-scenes look at the two vaccine candidates being developed by Monash University and the Doherty Institute.
How likely is it that we'll have a relatively quick fix for COVID-19, and what are the hurdles?
Dummy text
